Comparison of Metformin and Metformin Plus Liraglutide for Treating Metabolic Syndrome in Patients with Polycystic Ovarian Syndrome (PCOS)
DOI:
https://doi.org/10.70749/ijbr.v3i3.818Keywords:
Polycystic Ovary Syndrome (PCOS), Metformin, Liraglutide, Metabolic Syndrome, Weight Loss, Body Mass Index (BMI), Insulin Sensitivity, Obesity, Reproductive HealthAbstract
Background: This study compares the effectiveness of metformin (MET) monotherapy versus a combination of MET and liraglutide (LIRA) in managing metabolic syndrome in overweight women with polycystic ovary syndrome (PCOS), focusing on weight reduction and body mass index (BMI). Methods: A prospective cohort was conducted at Lady Dufferin Hospital, Karachi from April 2024 to Oct 2024, involving 70 women aged 18–40 years, diagnosed with PCOS based on Rotterdam criteria, and having a BMI ≥ 27.5 kg/m². Participants were randomly assigned into two groups: Group A received MET (1500 mg/day), and Group B received MET (1500 mg/day) plus LIRA (1.2 mg/day) for 12 weeks. Baseline and post-treatment outcomes, including weight, BMI, waist circumference, and lipid profiles, were analyzed. Results: Both treatment regimens significantly improved metabolic parameters. Group B demonstrated superior results with an average weight loss of 10.30 ± 1.30 kg and BMI reduction of 3.72 ± 0.67, compared to Group A’s weight loss of 5.99 ± 2.87 kg and BMI reduction of 2.24 ± 1.07 (p < 0.001). Improvements in triglyceride levels, HDL cholesterol, and waist circumference were more pronounced in Group B. However, no significant changes in hypertension parameters were observed in either group. Conclusion: The combination of MET and LIRA is more effective than MET monotherapy in managing metabolic syndrome in overweight PCOS patients. This dual therapy offers enhanced metabolic benefits, potentially improving both reproductive and overall health. Further long-term, multicenter studies are warranted to explore its broader impacts and sustainability.
Downloads
References
World Health Organization. (2025). Polycystic ovary syndrome. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
Zulfiqar, S., Noor, S., Rafique, H., Rehman, B., Babar, A., Shahid, T., Abid, A., Razzaq, M. A., Gulraiz, S., Tahir, S., & Anjum, I. (2022). Investigation of Prevalence and Awareness of Polycystic Ovary Syndrome among Pakistani Females. Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences, 59(1), 77–83. https://doi.org/10.53560/ppasb(59-1)703
Chang, K., Chen, J., & Chen, K. (2024). The Pathophysiological mechanism and clinical treatment of polycystic ovary syndrome: A molecular and cellular review of the literature. International Journal of Molecular Sciences, 25(16), 9037. https://doi.org/10.3390/ijms25169037
Barber, T. M. (2022). Why are women with polycystic ovary syndrome obese? British Medical Bulletin, 143(1), 4-15. https://doi.org/10.1093/bmb/ldac007
Kataoka, J., Olsson, M., Lindgren, E., Larsson, I., Schmidt, J., Benrick, A., & Stener-Victorin, E. (2023). Symptoms of anxiety and depression and health-related quality of life in women with severe obesity and polycystic ovary syndrome and the effect of a one year weight loss intervention. https://doi.org/10.21203/rs.3.rs-3542002/v1
Dubey, P., Reddy, S., Sharma, K., Johnson, S., Hardy, G., & Dwivedi, A. K. (2024). Polycystic ovary syndrome, insulin resistance, and cardiovascular disease. Current Cardiology Reports, 26(6), 483-495. https://doi.org/10.1007/s11886-024-02050-5
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., & Teede, H. (2023). The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. European Journal of Endocrinology, 189(2), S38-S64. https://doi.org/10.1093/ejendo/lvad098
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023). Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. Journal of Clinical Medicine, 12(18), 5915. https://doi.org/10.3390/jcm12185915
Siamashvili, M., & Davis, S. N. (2021). Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology, 14(9), 1081-1089. https://doi.org/10.1080/17512433.2021.1933433
Parkman, H. P., Rim, D. S., Anolik, J. R., Dadparvar, S., & Maurer, A. H. (2024). Glucagonlike peptide-1 receptor agonists: The good, the bad, and the ugly—Benefits for glucose control and weight loss with side effects of delaying gastric emptying. Journal of Nuclear Medicine Technology, 52(1), 3-7. https://doi.org/10.2967/jnmt.123.266800
Lyu, X., Lyu, T., Wang, X., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2021). The Antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight /Obese women with polycystic ovary syndrome: A systematic review and meta-analysis. International Journal of Endocrinology, 2021, 1-11. https://doi.org/10.1155/2021/6616693
Tamayo-Trujillo, R., Ruiz-Pozo, V. A., Cadena-Ullauri, S., Guevara-Ramírez, P., Paz-Cruz, E., Zambrano-Villacres, R., Simancas-Racines, D., & Zambrano, A. K. (2024). Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Frontiers in Nutrition, 11. https://doi.org/10.3389/fnut.2024.1398059
Chaudhary, S., & Kulkarni, A. (2024). Metformin: Past, present, and future. Current Diabetes Reports, 24(6), 119-130. https://doi.org/10.1007/s11892-024-01539-1
Parker, M., Warren, A., Nair, S., & Barnard, M. (2020). Adherence to treatment for polycystic ovarian syndrome: A systematic review. PLOS ONE, 15(2), e0228586. https://doi.org/10.1371/journal.pone.0228586
Cowan, S., Lim, S., Alycia, C., Pirotta, S., Thomson, R., Gibson-Helm, M., Blackmore, R., Naderpoor, N., Bennett, C., Ee, C., Rao, V., Mousa, A., Alesi, S., & Moran, L. (2023). Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocrine Disorders, 23(1). https://doi.org/10.1186/s12902-022-01208-y
Hoeger, K. M., Dokras, A., & Piltonen, T. (2020). Update on PCOS: Consequences, challenges, and guiding treatment. The Journal of Clinical Endocrinology & Metabolism, 106(3), e1071-e1083. https://doi.org/10.1210/clinem/dgaa839
Pugliese, G., De Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023). Liraglutide and polycystic ovary syndrome: Is it only a matter of body weight? Journal of Endocrinological Investigation, 46(9), 1761-1774. https://doi.org/10.1007/s40618-023-02084-6
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018). Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology, 14(7), 390-403. https://doi.org/10.1038/s41574-018-0016-2
Xing, C., Zhao, H., Zhang, J., & He, B. (2022). Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.945609
Heidarpour, M., Mojarad, M., Mazaheri-Tehrani, S., Kachuei, A., Najimi, A., Shafie, D., & Rezvanian, H. (2024). Comparative effectiveness of Antidiabetic drugs as an additional therapy to metformin in women with polycystic ovary syndrome: A systematic review of metabolic approaches. International Journal of Endocrinology, 2024, 1-11. https://doi.org/10.1155/2024/9900213
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
